盐酸罗哌卡因
| 中文名称 | 盐酸罗哌卡因 |
|---|---|
| 中文同义词 | 盐酸罗哌卡因(标准品);单水罗哌卡因盐酸盐;盐酸罗哌卡因一水物;罗哌卡因 盐酸水;盐酸罗哌卡因(碱基);ROPIVACAINE HCL 盐酸罗哌卡因;盐酸罗哌卡因对照品;盐酸罗哌卡因一水合物 |
| 英文名称 | Ropivacaine hydrochloride |
| 英文同义词 | (S)-1-propyl-2',6'-dimethylanilinoformoxylpiperidine monohydrochloride monohydrate;(S)-1-propyl-2',6'-dimethylanilinoformoxylpiperidine,monohydrochloride,monohydrate;(S)-Ropivaxaine hydrochloride;(S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride;Ropivacaine hydrochloride;(2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide Hydrochloride Hydrate;LEA-103;(S)-ropivacaine hydrochloride hydrate |
| CAS号 | 132112-35-7 |
| 分子式 | C17H26N2O.ClH.H2O |
| 分子量 | 328.88 |
| EINECS号 | 663-286-1 |
| 相关类别 | 麻醉剂类Narcotic;原料药;局部麻醉系列;中间体;其他科研原料药;医药原料;合成;小分子抑制剂，天然产物;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;麻醉类;Inhibitors;酰胺类局麻药;API;医药原料药-科研原料;有机化工中间体;医药原料和中间体;中间体类;原料;日用化学品;医用原料;化学试剂 |
| Mol文件 | 132112-35-7.mol |
| 结构式 |  |
盐酸罗哌卡因 性质
| 熔点 | 267-269°C |
|---|---|
| 比旋光度 | D20 -7.28° (c = 2 in water) |
| 储存条件 | 2-8°C |
| 溶解度 | H2O：可溶5mg/mL，澄清 |
| 形态 | 粉末 |
| 颜色 | 白色至类白色 |
| 旋光性 (optical activity) | [α]/D -9 to -12, c = 1 in methanol |
| InChIKey | VSHFRHVKMYGBJL-CKUXDGONSA-N |
| CAS 数据库 | 132112-35-7(CAS DataBase Reference) |
外科手术麻醉
-----硬膜外麻醉，包括剖宫产术
-----蛛网膜下腔麻醉
-----区域阻滞
急性疼痛控制
-----持续硬膜外输注或间歇性单次用药，如术后或阴道分娩镇痛
-----区域阻滞
盐酸罗哌卡因的一般副作用有低血压、恶心、心动过缓、焦虑、感觉减退。
Ropivacaine HCl (LEA-103) 是一种麻醉剂，通过可逆地抑制钠离子流入来阻断神经纤维上冲动的传导。IC50: sodium ion influxIC50: 402.7 μM (TREK-1 in COS-7 cell's membrane)
Ropivacaine HCl是一种局部麻醉剂。Ropivacaine HCl通过可逆抑制神经纤维中钠离子流引起神经阻滞。Ropivacaine HCl的pKa是~8.2。Ropivacaine HCl在高血浆浓度下具有诱导心血管毒性和CNS毒性的可能性。
Epidural administration of Ropivacaine hydrochloride monohydrate effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.
Ropivacaine hydrochloride monohydrate inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).
Ropivacaine hydrochloride monohydrate prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.
Ropivacaine hydrochloride monohydrate inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs.
| Animal Model: | Adult Sprague-Dawley rats (300–400g) |
| Dosage: | 1 μM |
| Administration: | Infusion (added to the perfusate reservoir) |
| Result: | Attenuated pressure-dependent increases in filtration coefficient (K f ). |
安全信息
| 危险品标志 | T,Xi |
|---|---|
| 危险类别码 | 26/27/28-41 |
| 安全说明 | 22-36/37/39-45-39-26 |
| 危险品运输编号 | UN 2811 6.1 / PGIII |
| WGK Germany | 3 |
| 海关编码 | 2933399090 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/25 | HY-B0563B | Ropivacaine hydrochloride | 5 mg | 218元 | |
| 2024/01/25 | HY-B0563B | 盐酸罗哌卡因 Ropivacaine hydrochloride | 132112-35-7 | 10 mg | 350元 |